Amgen to Present Long-Term Safety-Efficacy Data of Repatha (evolocumab) in Multiple studies- at AHA 2018
Shots:
- The presentation includes a collective analysis of 10 research abstracts plus results of OSLER-1 study- assessing Repatha (evolocumab) (420mg) in hypercholesterolemia patients for up to 5 yrs. & an additional RWE of FOURIER study assessing triglycerides in patients with CV risk
- FOURIER P-III (Further cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) involves assessing of Repatha (140mg SC q2w/420mg monthly) vs PBO with 1EP as CV death & strokes
- The OSLER-1 study is a part of PROFICIO (Program to Reduce LDL-C and cardiovascular Outcomes Following Inhibition of PCSK9 In different pOpulations) program assessing Repatha in 32 studies in ~ 37-800 patients
- Repatha is a mAb inhibiting PCSK9 and is approved in >60 countries including the US- Japan- Canada and EU
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
